Compare TKLF & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKLF | ALZN |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 7.5M |
| IPO Year | 2020 | 2021 |
| Metric | TKLF | ALZN |
|---|---|---|
| Price | $1.63 | $1.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 6.5K | ★ 99.5K |
| Earning Date | 12-19-2025 | 03-11-2026 |
| Dividend Yield | ★ 10.97% | N/A |
| EPS Growth | N/A | ★ 76.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $0.84 |
| 52 Week High | $3.92 | $2.68 |
| Indicator | TKLF | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 39.82 | 62.26 |
| Support Level | N/A | $1.69 |
| Resistance Level | $2.43 | $2.22 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 14.12 | 70.61 |
Tokyo Lifestyle Co Ltd is a retailer and wholesaler of Japanese beauty and health products, sundry products, electronic products, and other products. It sells its products through directly operated physical stores, online stores, and franchise stores and wholesale customers. It operates through directly operated physical stores, online stores and services, and franchise stores and wholesale customers segments, with the franchise stores and wholesale customers segment generating maximum revenue. Geographically, it generates maximum revenue from Hong Kong.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.